Q-omics provides the consensus-scored COX5B profile across patient tissues and cancer cell-line models. COX5B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, COX5B is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, COX5B protein abundance shows 21,413 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, LIHC, and GBM as cancer lineages where COX5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX5B survival associations across molecular data types. COX5B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX5B RNA expression–survival associations across cancer types. High COX5B expression shows unfavorable associations in UVM, LUAD, KICH, LAML, UCS and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for COX5B RNA expression.
This table summarizes COX5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COX5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX5B shows lower tumor expression in HNSC and higher tumor expression in LIHC, LUSC, LUAD, UCEC and BRCA. The LIHC box plot shows higher COX5B RNA expression in tumor versus normal tissue (log2 FC = +0.929, t-test p < 0.001).
This table shows molecular features associated with COX5B in patient tissues and cancer cell lines. In patient samples, COX5B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, COX5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
